Biocon Executive Chairperson Kiran Mazumdar-Shaw told Bloomberg's Francine Lacqua that a wave of expiring biologic patents provides a major runway to expand affordable cancer biosimilars and elevate the company above its current top-five global ranking. Speaking on the sidelines of the Bloomberg...
Source: [Bloomberg Markets](https://www.bloomberg.com/news/videos/2026-10-15/biocon-chair-ai-in-clinical-trials-is-the-holy-grail-video)